AGP Executive Report
Last update: 7 hours agoVaccine & Pharma Finance: Valneva reported €64.0M in first-half 2026 product sales (total revenues €65.8M), reaffirmed full-year guidance of €135–150M, and said it has a strong €121.5M cash position, while pointing to a restructuring program and upcoming regulatory decisions for its Lyme disease vaccine candidate within the next year. Urban Health & Climate: A new look at urban heat islands warns that hot-humid tropical cities can’t cool down fast enough, making heat risk worse for vulnerable residents as El Niño strengthens—highlighting practical fixes like shade, green roofs/walls, lighter surfaces, and better street airflow, though funding gaps leave many cities behind. Public Health & Drug Policy: Mauritius’ ongoing drug crisis is back in focus after the arrest of Gulshan Govind, with questions swirling around political responsibility and safeguards tied to public resources; the editorial urges a broader strategy beyond headline-driven outrage, while stressing the importance of due process.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
